Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is not how I would interpret the data. Granted I am good at kindergarten coloring, but I see no indication that changing the dosage at this point would provide any significant benefit. Care to elaborate?
So group 1 patients would be exclusive. They do not describe all combinations of the constants. Did any of the other 19 patients have APOE3 alleles?
Thanks for sharing this. So if n=21 for all patients, why is the sum of all patients from each group different?
Did the announcement of the call result in an increase of share price due to anticipation of results from ongoing clinical trials?
So what happens to the SAS patients if A2-73 is not approved?
Wasn't there a clinical trial started a long time ago? Still no results?
Hey Bas, I think that depends on the related activity of the compound. Early studies with potent musgarinic agonists resulted in some nasty side effects. The combination with sigma 1 agonists seems to resolve this effect. They have a cool synergy, targeting each others weakness.
Earlier research can be found by searching fo AF710B. There is some research that is not too old that also uses the same name: AF710B, a novel M1/s1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease
A3-71 has a different molecular structure and targets different muscarinic receptors. Muscarinic receptors play various roles throughout the body, which is why I believe A2-73 has benefit beyond memory loss. A2-73 interacts with all the muscarinic receptor types, which can help things like your heart, stomach, and muscle movement. A3-71 is designed to specifically target M1 receptors, or those that help with brain function. The molecule is also smaller and has a higher affinity for sigma 1 and M1 receptors, possibly making it more effective. It may not have some of the beneficial side effects that A2-73 has because of this. It has been a long time since I have researched these. A3-71 is what brought me here to invest.
Come on... one more scare. Shake, shake, shake...
Thanks for the supporting info. How much has been spent on and how long has the amyloid beta theory been chased?
Or, it is the result of covering at end of week, across the market. Hope's of some new magic pill, for the market or coronavirus.
This is a bunch of BS. There is no more of a cautious approach than any other biotech, and for some investors this slightly de-risks the stock due to a precision medicine approach. As long as the company is outright and forthcoming of the criteria and it can easily be duplicated to identify the target population, the bias you refer to is intelligent trial design. How do we define Alzheimers, Rhetts or Parkinsons... by symptoms, not the underlying cause. Why? Because to this point scientists and doctors have not been able to identify the cause. If Anavex can carve out a portion of all of these diseases, with the identification of biomarkers, the overall untreatable population shrinks, and we are that much closer to finding better medicine. Unless you are a regulator, how do you know they take this "bias" into consideration? And if they do, there will be insurmountable evidence against them with trial data. Approval is based on effects noted from trial design and inclusion criteria, not an imaginary bias.
The results are earth shattering for the completed trial. There was a study completed with a small sample of older patients that lead into this trial with young patients. Based on the results of that trial they recieved FTD. Any significant improvement from that awful disease is earth shattering, even if it saves only a small percentage of the population. A successful drug provides more information to get closer to other successful drugs. To this point no one knows the underlying cause of these CNS diseases or if they are reversible, only speculation. If one child is saved, it is one more than we have today.
Care to elaborate?
I'm saying the run up and down may have been due to leak. If you got news Biogen was going to partner with an alzheimers company and didn't know which one, what would you do?
If it was stock strength, why did we retrace so far? Interest just dried up? Was it all retail, the cabal? This long overdue run was a flop.
This kinda looks like a leak got out that Biogen was going to partner with an alzheimers company and we got caught up in the speculation...
There you go... volume 1.
Haven't seen this in a while - ask at $6.05. I know it is meaningless, but usually the gap is smaller than that.
”Unless you can watch your stock holding decline by 50% without becoming panic-stricken, you should not be in the stock market.”
“Calling someone who trades actively in the market an investor is like calling someone who repeatedly engages in one-night stands a romantic.”
Warren Buffett
Sorry, I don't buy any of that. Buffet does what Buffet does. When you have as much money as Buffet, you don't look for lottery stocks; a mild return that outpaces the overall market makes you millions.
I read posts like this and think of <fill in your favorite zombie movie here>.
Maybe the preppers are on to something.
Income in New York CityTypeIncome Amount Median Income
Household: $57,782
Individual: $50,825
Mean Income
Household: $93,196
Individual: $74,834
Per Capita Income $35,761
How is he all in? What did it cost? The company isn't even valued over $1 billion and he makes over $500k in salary. That is not exactly slumming it. As far as officing in NYC, why?
$26 million and not a single product to market? Geez, nearly 10%. Woop, woop. There is still nothing of proven value. Does he recieve a salary and options too?
How did Missling acquire so much common stock? Don't insiders have to disclose trades?
Makes you wonder, doesn't it? The link takes you to the article.
There are a couple. There are quite a few that haven't posted here in a while.
Is there anyone buying this stock?
Waiting for technical signal. We are still in a solid uptrend. May leave a little on the table, but from here that number keeps rising.
Wasn't he the coffee guy?
Just got this message for some reason. I see your point about the share price.
Off memory... there were a couple of trial extensions. The first was an extension of the main study objectives. The separate extension included separate study objectives. What is the purpose of the PDD extension? Is it listed with original study?
Well, that really doesn't say much for timely.
Last Update Posted : November 19, 2019
The first post was way after start.
First Posted : January 2, 2019
Actual Study Start Date : July 3, 2018
The trial is listed as a Phase 2 and Phase 3 trial, described as Phase 2b/3. Are patients that finish the Phase 2 portion just supposed to wait for all others before transitioning to Phase 3? It is a 48 week study, so when was the first patient dosed?
Do you know when this was last updated? That site can be a terrible resource for timely updates.
With my recent luck with mail, it probably got lost. They won't issue a refund on this one though.
Did we ever get the enrollment news?
Missling pre-announces alot of things that don't transpire. People are getting callused to these expectations. I don't think full enrollment at this point is substantial to investors either. Show us data from something other than the P2a alzheimers trial. I don't think that will be years...
You seem like a numbers person. What are the odds that the high concentration group of A2-73 would also correlate with this subset of ChEI treated patients?